Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

  title={Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats},
  author={Kosuke Kaji and Hitoshi Yoshiji and Yasuhide Ikenaka and Ryuichi Noguchi and Yosuke Aihara and Akitoshi Douhara and Kei Moriya and Hideto Kawaratani and Yusaku Shirai and Junichi Yoshii and Koji Yanase and Mitsuteru Kitade and Tadashi Namisaki and Hiroshi Fukui},
  journal={Journal of Gastroenterology},
BackgroundDipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic liver diseases, the effect of DPP4-I on liver fibrosis development is still obscure. This study was designed to elucidate the effect of DPP4-I on liver fibrosis development in conjunction with the activated hepatic stellate cells (Ac-HSCs).MethodsThe antifibrotic effect of DPP4-I was assessed in vivo and in vitro using… 

Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction.

Gemigliptin protected against HSC activation and liver fibrosis by alleviating mitochondrial dysfunction and ROS production, indicating its potential as a strategy for preventing the development of liver disease.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats

Collectively, TGR5 agonist and DPP-4 inhibitor appears to be a novel strategy against liver fibrosis under diabetic conditions.

Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.

Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice

It is demonstrated that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.

Alleviation of Carbon-Tetrachloride-Induced Liver Injury and Fibrosis by Betaine Supplementation in Chickens

The results highlight the antioxidant ability of betaine, which alleviates CCl4-induced fibrogenesis process along with the suppression of hepatic stellate cells activation, and suggest betaine can be used as a potent nutritional or therapeutic factor for reducing liver fibrosis.

Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis

Carvedilol may alleviate liver cirrhosis in rats by inhibiting HSC activation, proliferation, invasion and collagen synthesis, and may be a potential treatment of early-stage liver Cirrhosis.

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis

Investigation of whether a profibrotic DPP4 phenotype is present in lung tissue from patients with idiopathic pulmonary fibrosis found a reduced frequency of primary DPP 4+ fibroblasts in IPF tissue using flow cytometry, and an absence in pathohistological features of IPF.



Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

In vitro study showed that STI-571 markedly attenuated PDGF-BB-induced proliferation and migration and alpha-SMA and alpha2-(I)-procollagen mRNA of activated HSC in a dose-dependent manner, which may provide an effective new strategy for antifibrosis therapy.

Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice

STI-571 treatment effectively attenuated liver fibrogenesis and improved in liver regeneration in vivo and induced apoptosis in HSCs both in vitro and in vivo.

Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts.

Inhibition of DP IV-like enzymatic activity may represent a promising therapeutic approach for the treatment of fibrotic skin disorders and keloid-derived skin fibroblasts in vitro.

Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.

In vitro study showed that SAB inhibited the Ald-induced HSC proliferation and in vitro angiogenesis in a dose-dependent manner, indicating that Ald plays a pivotal role in the progression of NASH.

The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat.

Eplerenone attenuated the development of BDL-induced hepatic fibrosis by reducing oxidative stress, suppressing activated hepatic stellate cells and decreasing plasma ATII levels.

Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

The results suggested that the RAS, especially AT‐II and AT1‐R interaction plays a pivotal role in liver fibrosis development through HSC activation, and both CA and PE may provide an effective new strategy for anti–liver fibrosis therapy.

Mechanisms of hepatic fibrogenesis.

Clinical and translational implications of these advances have become clear, and have begun to impact significantly on the management and outlook of patients with chronic liver disease.

Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling.

If DPPIV proves to be indeed a critical step required for inhibiting NPY’s contractile and pro-atherosclerotic effect and potentiating its angiogenic activities, abnormally low DPP IV expression and activity could be a risk factor for hypertension and ischemic cardiovascular diseases, in which NPY has already been implicated28.